“Leading journal presents a proof of principle study for Cilian’s expression technology CIPEXSystem to produce monoclonal antibody candidates. Münster, Germany, February 1, 2017, Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that mABs, the international, peer-reviewed, open-access, online publication journal, has published an article entitled: Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity.”